August 15, 2025

A Diagnosis of Stage IV Lung Cancer at 18 Has Tested My Faith—and Made It Stronger

The main symptom that eventually led to my diagnosis of stage IV adenocarcinoma non–small cell lung cancer (NSCLC) started in the fall of 2009. I was just 17 and in my freshman year at college when I ...

The ASCO Post

August 15, 2025

Alcohol-Associated Cancer Death Rates Are Climbing

Alcohol-associated cancer deaths have doubled in the United States, disproportionately affecting men and those aged 55 or older, according to the results of an observational study presented at the 202...

The ASCO Post

August 15, 2025

ASCO Names 2025 Q1, Q2 FASCO Recipients

Launched in 2007 and formerly called the ASCO Statesman Award, the FASCO distinction honors members for their extraordinary volunteer service, engagement, and dedication to American Society of Clinica...

The ASCO Post

August 14, 2025

Why Sarcomas Require Expert, Multidisciplinary Cancer Care

Sarcomas are one of the rarest and most complex cancer types, making up less than 1% of all new cancer diagnoses in the United States.

Baptist Health South Florida

August 12, 2025

UC Irvine clinical research teams advance science for the common good

As the only academic institute in Orange County, UC Irvine prioritizes advancements in science through clinical research.

UCI Health

August 11, 2025

UCI Health leads the charge in colorectal cancer education

Faculty from the Chao Digestive Health Institute set up an event to educate patients on the importance of colonoscopies.

UCI Health

August 06, 2025

Nivolumab Plus Ipilimumab in Advanced Ovarian and Endometrial Clear Cell Cancers

In an Australian–New Zealand phase II trial (MoST-CIRCUIT) reported in JAMA Oncology, Gao et al found that the combination of nivolumab and ipilimumab showed “encouraging activity” in patients with ad...

The ASCO Post

August 05, 2025

Polatuzumab Vedotin–Based Regimen Improves Overall Survival in Refractory DLBCL

Combining the CD79b-directed antibody-drug conjugate polatuzumab vedotin-piiq with rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved survival outcomes in patients with transplan...

The ASCO Post

August 05, 2025

Advancing Geriatric Oncology: Where We Have Been and Where We Are Going

The aging population is rapidly growing, with the number of older adults rising steadily each year. In the 1980s, experts predicted a rise in the number of older patients with cancer, yet we were unpr...

The ASCO Post